Sponsors (35)
The bill strengthens federal control, reporting, and sentencing consistency for xylazine to support enforcement and public-health action, but does so at the cost of greater criminalization risk, access and administrative burdens for legitimate users and providers, and added compliance and enforcement costs.
Law enforcement, prosecutors, and courts will have a clearer, consistent legal definition and scheduling of xylazine, enabling more uniform investigations, prosecutions, and interagency coordination.
People with substance-use disorders, health providers, and hospitals will get clearer regulatory rules and better data on xylazine prevalence and harms, improving public-health responses and clinical/supply-chain handling.
Farmers, veterinarians, hospitals, and manufacturers get temporary operational flexibility (60-day vet possession, 1-year delays on labeling/packaging, no immediate capital security upgrades, expedited agency review) that helps avoid sudden supply or treatment disruptions.
People who use or possess xylazine and low-level distributors face expanded criminal exposure and higher likelihood of arrest or prosecution because the bill broadens coverage (including salts/isomers) and tightens controls.
Patients who rely on legitimate xylazine-containing medications and veterinarians may experience reduced access, treatment interruptions, or higher administrative burdens as stricter controls and practitioner requirements take effect.
Hospitals, pharmacies, manufacturers, and federal agencies will face increased compliance, recordkeeping, and administrative costs to meet new scheduling, labeling, and reporting requirements.
Based on analysis of 7 sections of legislative text.
Reclassifies xylazine and products containing it as Schedule III, updates related definitions, phases in compliance rules, directs sentencing review, and requires multi-stage federal reports.
Introduced February 12, 2025 by Catherine Marie Cortez Masto · Last progress February 12, 2025
Designates xylazine (including salts, isomers, and related forms) and any product containing it as a Schedule III controlled substance, bringing manufacture, distribution, possession, and recordkeeping under CSA rules. The measure updates definitions for practitioners and users to account for animal uses, delays several Schedule III compliance requirements for xylazine during transition periods, directs the Sentencing Commission to review penalties for xylazine-related offenses, and requires multiple DOJ/FDA/HHS reports on xylazine prevalence, origins, and related risks.